Is DAT imaging abnormality in Normal Pressure Hydrocephalus always suggestive of degeneration? Evidences from three cases
Objective: To study parkinsonism in iNPH, in order to shed light on its pathogenesis, understand potential overlap with idiopathic parkinsonismsand its impact on the clinical outcome.…Periventricular hyperintensities and axial symptom of Parkinson’s disease
Objective: To investigate which area of white matter hyperintensities (WMH) is associated with motor symptom of Parkinson’s disease (PD) independently of dopaminergic depletion. Background: WMH…Structural connectivity changes in G2019S-LRRK2 gene mutation carriers without manifest Parkinson’s disease
Objective: We hypothesised that abnormal sprouting of serotonergic terminals in the hypothalamus may lead to abnormal structural connectivity, which can be measured with diffusion tensor…Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study
Objective: We aimed to evaluate the role of astroglia activation in Parkinson's disease (PD) using [11C]BU99008 PET, a novel radioligand with high specificity and selectivity…Mindfulness Based Stress Reduction in People with Parkinson’s Disease and their Carepartners
Objective: To assess the feasibility and impact of mindfulness based stress reduction (MBSR) on people with Parkinson’s disease (PD) and their carepartners. Background: Non-motor symptoms…Prevalence and associated risk factors of early morning off among the patients with Parkinson’s disease in China
Objective: To explore the prevalence and associated risk factors of early morning off (EMO) among outpatients with Parkinson’s disease (PD) in China. Background: PD is…Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study
Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients
Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment
Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…
- « Previous Page
- 1
- …
- 125
- 126
- 127
- 128
- 129
- …
- 388
- Next Page »